KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells

BACKGROUNDS: Immune checkpoint blockade has revolutionized cancer treatment and has improved the survival of a subset of patients with cancer. However, numerous patients do not benefit from immunotherapy, and treatment resistance is a major challenge. Krüppel-like factor 12 (KLF12) is a transcriptio...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yujia, Zhang, Hao, Xiao, Chu, Deng, Ziqin, Fan, Tao, Zheng, Bo, Li, Chunxiang, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432659/
https://www.ncbi.nlm.nih.gov/pubmed/37586772
http://dx.doi.org/10.1136/jitc-2023-007286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432659/
https://www.ncbi.nlm.nih.gov/pubmed/37586772
http://dx.doi.org/10.1136/jitc-2023-007286

Ejemplares similares